Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OncoVista Innovative Therapies, Inc. (OVIT)
San Antonio, TX, US
OncoVista Innovative Therapies, Inc. does not have significant business. Previously, it engaged in development of targeted anticancer therapies by utilizing tumor-associated biomarkers. The company was founded in 2004 and is based in San Antonio, Texas.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -75.00% | +0.00% | +0.00% | -99.92% | -99.85% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-71.4% Q3'15: -200.0% (vs Q3'14)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'15: +20.6% (vs Q3'14)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q3'15: +6.6% (vs Q3'14)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q3'15: -0.38× (vs Q3'14)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Centrecourt Asset Management LLC | 1.84M | 9.10% | 1.84M | — | 1.84M | — | IA | United States | 2009-02-12 | ↗ |
| 2 | Richard Smithline | 1.84M | 9.10% | 1.84M | — | 1.84M | — | IN | United States | 2009-02-12 | ↗ |
| 3 | Charles E. Davidson | 1.71M | 7.93% | — | 1.71M | — | — | IN | United States | 2014-02-14 | ↗ |
| 4 | Joseph M. Jacobs | 1.71M | 7.93% | — | 1.71M | — | — | IN | United States | 2014-02-14 | ↗ |
| 5 | Wexford Capital LP | 1.71M | 7.93% | — | 1.71M | — | — | PN | Delaware | 2014-02-14 | ↗ |
| 6 | Wexford GP LLC | 1.71M | 7.93% | — | 1.71M | — | — | OO | Delaware | 2014-02-14 | ↗ |
| 7 | Wexford Spectrum Trading Limited | 1.71M | 7.93% | — | 1.71M | — | — | CO | Cayman Islands | 2014-02-14 | ↗ |
| 8 | CAMOFI Master LDC | 1.56M | 7.70% | 1.56M | — | 1.56M | — | OO | Cayman Islands | 2009-02-12 | ↗ |
| 9 | CAMHZN Master LDC | 285.3K | 1.40% | 285.3K | — | 285.3K | — | OO | Cayman Islands | 2009-02-12 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexander L. Weis | Chairman, Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer and Secretary | 322.0K | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OVIT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
